{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:50:55Z","timestamp":1787017855228,"version":"build-2736575974"},"reference-count":28,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA201487"],"award-info":[{"award-number":["R01 CA201487"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009142","name":"Cancer Care Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011676","name":"Elekta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025092","name":"Ministry of Health, Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","award":["24-20-12-KWAN"],"award-info":[{"award-number":["24-20-12-KWAN"]}],"id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Lymphedema is a chronic complication of breast cancer treatment, and early intervention is crucial to reduce morbidity. This study evaluated the role of blood-based cytokine biomarkers in the prognostication of breast cancer\u2013related lymphedema (BCRL) to improve risk prediction. A secondary analysis of inflammatory biomarkers for BCRL was performed using a previously published cohort of 147 patients with breast cancer who had undergone serum cytokine profiling during their treatment at the Princess Margaret Cancer Centre from 2010 to 2014. Prognostic cytokine variables for lymphedema were selected by regression analysis and independence from known clinical risk factors. Regression-based modeling was employed to integrate prognostic variables for the prediction of lymphedema occurrence. We identified the immunostimulatory cytokine IFN\u03b12A as a potential biomarker for lymphedema development [OR, 3.10; 95% confidence interval (CI), 1.05\u20139.51; P = 0.042], independent from known clinical risk factors. Furthermore, Kaplan\u2013Meier analysis demonstrated 3-year lymphedema-free survival of 95% (90%\u2013100%) versus 85% (77%\u201394%) for below versus above median concentrations of IFN\u03b12A (P = 0.026). In combination with an established clinical risk regression-based model, patients identified as high risk based on clinical factors alone were able to be correctly reclassified as low risk by IFN\u03b12A in 31% (eight of 26) of cases. Our combined logistic regression model using both IFN\u03b12A and clinical risk score achieved an AUC of 0.895 (95% CI, 0.796\u20130.971) and Brier score of 0.101 (95% CI, 0.061\u20130.149), representing a favorable improvement compared with the logistic regression model using clinical risk factors alone. IFN\u03b12A in combination with established clinical risk factors may be useful for improving BCRL prognostication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The cytokine IFN\u03b12A was identified as a potentially complementary biomarker to improve the stratification of high- and low-risk patients for BCRL. This will help enable earlier intervention to reduce long-term morbidity for those at high risk for lymphedema while minimizing burdensome interventions for those at low risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0541","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:01:56Z","timestamp":1770274916000},"page":"456-465","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer\u2013Related Lymphedema"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0752-0190","authenticated-orcid":false,"given":"Alison J.","family":"Wu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03dbr7087","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Toronto 1 MD Program, Temerty Faculty of Medicine, , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 2 Research Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3203-4497","authenticated-orcid":false,"given":"Neil","family":"Lin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03dbr7087","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Toronto 1 MD Program, Temerty Faculty of Medicine, , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03dbr7087","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Toronto 3 Institute of Medical Science, Temerty Faculty of Medicine, , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8402-9235","authenticated-orcid":false,"given":"Jie","family":"Su","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 4 Biostatistics Division, , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5744-4993","authenticated-orcid":false,"given":"Cherie","family":"Lin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03dbr7087","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Toronto 3 Institute of Medical Science, Temerty Faculty of Medicine, , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6409-3539","authenticated-orcid":false,"given":"Madison-Shira","family":"Hossack","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 2 Research Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7695-1839","authenticated-orcid":false,"given":"Wei","family":"Shi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 2 Research Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-9379","authenticated-orcid":false,"given":"Farnoosh","family":"Abbas-Aghababazadeh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 5 Princess Margaret Bioinformatics and Computational Genomics Laboratory, , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0257-8856","authenticated-orcid":false,"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 4 Biostatistics Division, , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-0079","authenticated-orcid":false,"given":"Benjamin","family":"Haibe-Kains","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 5 Princess Margaret Bioinformatics and Computational Genomics Laboratory, , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03dbr7087","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Toronto 6 Department of Computer Science, , Toronto, Canada."},{"name":"7Ontario Institute for Cancer Research, Toronto, Canada."},{"name":"8Vector Institute for Artificial Intelligence, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-1263","authenticated-orcid":false,"given":"Simona F.","family":"Shaitelman","sequence":"additional","affiliation":[{"name":"9Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas."},{"name":"10The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-7607","authenticated-orcid":false,"given":"Melissa B.","family":"Aldrich","sequence":"additional","affiliation":[{"name":"10The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas."},{"name":"11UTHealth Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-6486","authenticated-orcid":false,"given":"Fei-Fei","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03dbr7087","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Toronto 12 Department of Radiation Oncology, Temerty Faculty of Medicine, , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03dbr7087","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Toronto 13 Department of Medical Biophysics, Temerty Faculty of Medicine, , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 14 Radiation Medicine Program, , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2651-2402","authenticated-orcid":false,"given":"Jennifer Y.Y.","family":"Kwan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network 2 Research Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03dbr7087","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Toronto 3 Institute of Medical Science, Temerty Faculty of Medicine, , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03dbr7087","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Toronto 12 Department of Radiation Oncology, Temerty Faculty of Medicine, , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 14 Radiation Medicine Program, , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2026030306313195100_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/tbj.12586","article-title":"The increasing role of lymphedema screening, diagnosis and management as part of evidence-based guidelines for breast cancer care","volume":"22","author":"Vicini","year":"2016","journal-title":"Breast J"},{"key":"2026030306313195100_bib2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.cyto.2013.05.015","article-title":"Cytokines are systemic effectors of lymphatic function in acute inflammation","volume":"64","author":"Aldrich","year":"2013","journal-title":"Cytokine"},{"key":"2026030306313195100_bib3","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2012.41.8574","article-title":"Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review","volume":"30","author":"Paskett","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026030306313195100_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00063030-200620060-00007","article-title":"An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis","volume":"20","author":"Cheung","year":"2006","journal-title":"BioDrugs"},{"key":"2026030306313195100_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/PRS.0b013e3182450b2d","article-title":"Regulation of adipogenesis by lymphatic fluid stasis: part I. Adipogenesis, fibrosis, and inflammation","volume":"129","author":"Zampell","year":"2012","journal-title":"Plast Reconstr Surg"},{"issue":"Suppl 8","key":"2026030306313195100_bib6","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/cncr.27467","article-title":"Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care","volume":"118","author":"Hayes","year":"2012","journal-title":"Cancer"},{"key":"2026030306313195100_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2022.1628","article-title":"Risk factors and racial and ethnic disparities in patients with breast cancer\u2013related lymphedema","volume":"8","author":"Montagna","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026030306313195100_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-019-0072-5","article-title":"Cancer-associated secondary lymphoedema","volume":"5","author":"Rockson","year":"2019","journal-title":"Nat Rev Dis Primer"},{"key":"2026030306313195100_bib9","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s11764-015-0507-2","article-title":"Differences in limb volume trajectories after breast cancer treatment","volume":"10","author":"Smoot","year":"2016","journal-title":"J Cancer Surviv"},{"key":"2026030306313195100_bib10","doi-asserted-by":"crossref","first-page":"330e","DOI":"10.1097\/PRS.0000000000009866","article-title":"The vicious circle of stasis, inflammation, and fibrosis in lymphedema","volume":"151","author":"Brown","year":"2023","journal-title":"Plast Reconstr Surg"},{"key":"2026030306313195100_bib11","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1371\/journal.pmed.0030254","article-title":"Inflammatory manifestations of experimental lymphatic insufficiency","volume":"3","author":"Tabibiazar","year":"2006","journal-title":"PLoS Med"},{"key":"2026030306313195100_bib12","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.3390\/ijms25073907","article-title":"The role of inflammation in lymphedema: a narrative review of pathogenesis and opportunities for therapeutic intervention","volume":"25","author":"Bowman","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026030306313195100_bib13","doi-asserted-by":"crossref","first-page":"e52021","DOI":"10.1371\/journal.pone.0052021","article-title":"Prospective transcriptomic pathway analysis of human lymphatic vascular insufficiency: identification and validation of a circulating biomarker panel","volume":"7","author":"Lin","year":"2012","journal-title":"PLoS One"},{"key":"2026030306313195100_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/lrb.2013.0024","article-title":"Cytokine candidate genes predict the development of secondary lymphedema following breast cancer surgery","volume":"12","author":"Leung","year":"2014","journal-title":"Lymphat Res Biol"},{"key":"2026030306313195100_bib15","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1096\/fj.12-222695","article-title":"Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema","volume":"27","author":"Avraham","year":"2013","journal-title":"FASEB J"},{"key":"2026030306313195100_bib16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/lrb.2016.0010","article-title":"Pathological changes of lymphedematous skin: increased mast cells, related proteases, and activated transforming growth factor-\u03b21","volume":"14","author":"Di","year":"2016","journal-title":"Lymphat Res Biol"},{"key":"2026030306313195100_bib17","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1002\/ctm2.758","article-title":"TGF-\u03b21 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation","volume":"12","author":"Baik","year":"2022","journal-title":"Clin Transl Med"},{"key":"2026030306313195100_bib18","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/cas.14457","article-title":"Potential role of transforming growth factor-beta 1\/Smad signaling in secondary lymphedema after cancer surgery","volume":"111","author":"Sano","year":"2020","journal-title":"Cancer Sci"},{"key":"2026030306313195100_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jvsv.2022.12.022","article-title":"Plasma cytokine levels as prognostic biomarkers and reparative microsurgery outcome measures for breast cancer-related lymphedema","volume":"11","author":"Vang","year":"2023","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"2026030306313195100_bib20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/cancers15030676","article-title":"Plasma cytokines\/chemokines as predictive biomarkers for lymphedema in breast cancer patients","volume":"15","author":"Vang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026030306313195100_bib21","doi-asserted-by":"crossref","first-page":"e2024373","DOI":"10.1001\/jamanetworkopen.2020.24373","article-title":"Development and validation of a risk model for breast cancer\u2013related lymphedema","volume":"3","author":"Kwan","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026030306313195100_bib22","doi-asserted-by":"crossref","first-page":"pkaa037","DOI":"10.1093\/jncics\/pkaa037","article-title":"Inflammatory biomarkers, hematopoietic stem cells, and symptoms in breast cancer patients undergoing adjuvant radiation therapy","volume":"4","author":"Shi","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2026030306313195100_bib23","doi-asserted-by":"crossref","first-page":"e2455383","DOI":"10.1001\/jamanetworkopen.2024.55383","article-title":"External validation of a 5-factor risk model for breast cancer\u2013related lymphedema","volume":"8","author":"Lin","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026030306313195100_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12967-015-0477-1","article-title":"Diurnal rhythms of serum and plasma cytokine profiles in healthy elderly individuals assessed using membrane based multiplexed immunoassay","volume":"13","author":"Altara","year":"2015","journal-title":"J Transl Med"},{"key":"2026030306313195100_bib25","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/jir.2006.26.568","article-title":"Influence of IFN- \u03b1 and IFN- \u03b3 on lymphangiogenesis","volume":"26","author":"Shao","year":"2006","journal-title":"J Interferon Cytokine Res"},{"key":"2026030306313195100_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/84651","article-title":"Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3","volume":"7","author":"M\u00e4kinen","year":"2001","journal-title":"Nat Med"},{"key":"2026030306313195100_bib27","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/s41598-019-40078-8","article-title":"Inflammatory cytokines and change of Th1\/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"2026030306313195100_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0188-4409(00)00272-1","article-title":"Serum immunoglobulins, IL-1beta, IL-2, and IFN-gamma gamma level in patients with lymphedema treated with ortho-beta-hydroxy-ethyl rutosides (HR)","volume":"32","author":"de Schenquer","year":"2001","journal-title":"Arch Med Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0541\/3735952\/crc-25-0541.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/456\/3744653\/crc-25-0541.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/456\/3744653\/crc-25-0541.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T11:31:42Z","timestamp":1772537502000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/3\/456\/774947\/Identification-of-a-Cytokine-Biomarker-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0541","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31452922","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31452934","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31452946","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31452925","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31452931","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31452943","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31452937","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31452928","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8334226","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}